Difference between revisions of "TTN-AS1"
(→Characteristics) |
|||
| Line 1: | Line 1: | ||
| − | ''TTN-AS1 | + | ''TTN-AS1/miR133b/FSCN1'' regulatory axis provides potential targets for anti-Esophageal Squamous Cell Carcinoma (ESCC) therapies. |
==Annotated Information== | ==Annotated Information== | ||
| Line 9: | Line 9: | ||
===Function=== | ===Function=== | ||
| − | ''TTN-AS1'' plays a vital role in ESCC progression and metastasis. ''TTN-AS1'' enhances ''Snail1'' and ''FSCN1'' levels by competitively binding to miR-133b, resulting in the promotion of EMT cascades. Meanwhile, ''TTN-AS1'' also induces HuR via its sponge activity, which further activates the ''FSCN1/β-catenin'' signaling pathway. In addition, ''TTN-AS1''/''miR-133b''/''FSCN1'' is a potential prognostic biomarker panel in ESCC carcinogenesis <ref name="ref1" />. | + | Novel long non-coding RNA ''TTN-AS1'' plays a vital role in ESCC progression and metastasis. ''TTN-AS1'' enhances ''Snail1'' and ''FSCN1'' levels by competitively binding to miR-133b, resulting in the promotion of EMT cascades. Meanwhile, ''TTN-AS1'' also induces HuR via its sponge activity, which further activates the ''FSCN1/β-catenin'' signaling pathway. In addition, ''TTN-AS1''/''miR-133b''/''FSCN1'' is a potential prognostic biomarker panel in ESCC carcinogenesis <ref name="ref1" />. |
===Regulation=== | ===Regulation=== | ||
Revision as of 08:58, 20 December 2018
TTN-AS1/miR133b/FSCN1 regulatory axis provides potential targets for anti-Esophageal Squamous Cell Carcinoma (ESCC) therapies.
Contents
Annotated Information
Name
TTN-AS1: TTN antisense RNA 1 (HGNC nomenclature).
Characteristics
TTN-AS1 has a chromosomal location of 2q31.2 (HGNC nomenclature).
Function
Novel long non-coding RNA TTN-AS1 plays a vital role in ESCC progression and metastasis. TTN-AS1 enhances Snail1 and FSCN1 levels by competitively binding to miR-133b, resulting in the promotion of EMT cascades. Meanwhile, TTN-AS1 also induces HuR via its sponge activity, which further activates the FSCN1/β-catenin signaling pathway. In addition, TTN-AS1/miR-133b/FSCN1 is a potential prognostic biomarker panel in ESCC carcinogenesis [1].
Regulation
TTN-AS1 promotes expression of transcription factor Snail1 by competitively binding miR-133b, resulting in the epithelial-mesenchymal transition (EMT) cascade. Moreover, TTN-AS1 also induces FSCN1 expression by sponging miR-133b and upregulation of mRNA-stabilizing protein HuR, which further promotes ESCC invasion cascades [1].
Diseases
- Esophageal Squamous Cell Carcinoma (ESCC) [1]
Expression
TTN-AS1 as an oncogene is highly expressed in ESCC tissues and cell lines, and promotes ESCC cell proliferation and metastasis [1].
| Experiment | Forward primer | Reverse primer |
|---|---|---|
| qRT-PCR | NA | NA |
Labs working on this lncRNA
- Department of Engineering Research Center of Peptide Drug Discovery and Development, Nanjing, P.R. China. [1]
- Department of State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, P.R. China. [1]
- Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, Australia. [1]
- School of Pharmacy and The Yunnan Provincial Key Laboratory of Natural Drug and Pharmacology, Kunming Medical University, Kunming, Yunnan, P.R. China. [1]
- Department of Engineering Research Center of Peptide Drug Discovery and Development, Nanjing, P.R. China. [1]
References
Sequence
>gi|100506866|ref|NR_038271.1| Homo sapiens TTN antisense RNA 1 (TTN-AS1), long non-coding RNA
000081 GGGGCTTCTG GCCGTTCTGT TGGAGCGCCT CTGACTGACT TCCCCCATGT GTCCGTGTGG CCACACCGTG CTACTTTCAG 000160
000161 AGGCAGTGGG CTTTTCGCTA AGGGATAAAA AGAAGTAAAA CCTTGCCTTT AGCGCAGCTC TCCTTCACTG GGCAGATTGC 000240
000241 TCTCCCTCCC CACTCTCCCA GGCCCAAATT GGATCTCAGC GCCTGGGAGC TCCAACTTTA GCAAGTGCGA AATCCTGTCT 000320
000321 TCGGTTTTGG AATTTTCATC CGCACAGACT ATATCAGCCA CGGATAGGAT ATGTGAGAAT ACCAGCATGT CAAGGCTGGG 000400
000401 AATCATCCTT AGGCATCACC TAGCCAGTCC TGCCTCTCAT TTTAAGATGA TAGCCAATGA CTCTACTTCC TCCATCACTG 000480
000481 ATTGGCTCAT TCCATTGTAC TTCCATGCTG TCCCTGGAGG ACAGTGTGAC AACTGGAGTG CCAGGAGGAC CAGGAACTTT 000560
000561 GAATGGATAT TGGGCTACAG TAGGCTCTGA ATTGAGAGAA TAGACGCCTT GATGGCTCCT CTGGCAGTTC TTGATGACCA 000640
000641 TGGATGAGCT AATGGCTGTG GTCTCAATGG TGGCTTCTTG AGGAACTACT TACAGATTGG ATCATGTGCT GTTTTGGGAT 000720
000721 CTGAAGGTGG ACTGAACTTT CCAGGTCCAG CTGCATTTTC AGCACATACT CTGAAGACAT AGCTGATTGA GAAACTTACC 000800
000801 AAACTGATAT TTGGCTGTTA TTGGAGAGGC CTGAACTGGT TCACCAACAC CATACATGTT TTCTGCAGCA ACTCTGAAGA 000880
000881 TGTACTCTTT ATTGGGGATT AATTTGGTGG CCTTGAAGTT TGTATCCTTG ACGGTGGATG AGAGCTTGTG CCACACTTCA 000960
000961 CTATCAGTTG CTCGTCTCTC CACAACATAG TTTGTGATCT TAGATCCACC ATCATCGCGT GGTGGGTTCC ATGTTAGAAG 001040
001041 ACATGACTCA TTGGTTACAT CTGTGATGTC AAAGGCAGCT GGTGGTCCGG GTTTATCTGT GTATGGCATT ACAGATGCAG 001120
001121 AAAAAAAAAT TGTTCACCAT TTTTTTTATT TTTTTCTTTC AAGAAAGTAA CTGCAAAGAG TTTATCCCCT TTTAAAATGA 001200
001201 GAACCTTCCT TACCTAAGAC GTTCACTTCC ACCACAGCAG TGGCCCGGCC ACACACATTC ACAGCCTCAA TGATATATGT 001280
001281 GCCAGTGTCA CTTCTCTTAC TATCAACAAT AGTCACTGTG GATTTCTTAG GGACATTTTC AATGGTAATT CTTTTGTCCT 001360
001361 GCTTCAGAAT CATATCAGCC TTTGTCCAAG TTATTTTAGG TTCAGGTTTT CCGGTTACGG TGGCAGGAAG TTCAATCTTG 001440
001441 GTCCCAGCTT TTACAGTGAG ACCAGCAAGG AGCTTCACAT CGAGGAAGAT TTCTGGGGCC TCTGAATTGG AAAAGATTAT 001520
001521 TTATGATGTT ATCAAGTTCA AGCAGATTTA AGGTTCTCCA CAGGCAACCC ATTTATCAGA ACCACGTGGA CATCTTTCAA 001600
001601 CTATCCTGGA CAACAACCAT GTTATTTCTT AGCCATTGGA CTTCCACCTT ATCTTTATTG AGTTCTGCTA AAAAGACAAC 001680
001681 ATCAGCACCA GGGGCTTCAA GAATATCTTG TGGAGGCCTG ATGATCTCAA CAGGAATTTC TGGAAAGAAA ATGTGAAATA 001760
001761 AATACAAATA TGTTTACATT TTGATTAACA ATTTTAAAAA ATTGGTAACA TTAGAATTGT TTTTTCACTT AATATGTACC 001840
001841 TTCCACAAAA AGTCTAGCAC GAGACTTCCT GTCTTCTACC CCGCAAGCAT ATTCACACTC ATCATCCAGC CTGCAATCTT 001920
001921 TTATAATGAG TCTGTGTATA CTTCCATCTT TTTCAAATTT GTATCTAAAG GAGACATTGG ATTATCAGTT AGCTTGCAAT 002000
002001 GATGGCCACT AAATTGTCAA AAGTGTATAT ATAGCTACAG AAATAGAGAA TAAAAAGATC TTGCTTACT
